ABMD

AbiomedNasdaqGS:ABMD Stock Report

Market Cap

US$16.1b

7D

-2.9%

1Y

28.6%

Updated

16 Sep, 2021

Data

Company Financials +
ABMD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance2/6
Financial Health6/6
Dividends0/6

ABMD Overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.

Rewards

Earnings are forecast to grow 31.02% per year

Risk Analysis

No risks detected for ABMD from our risk checks.

Abiomed Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Abiomed
Historical stock prices
Current Share PriceUS$355.18
52 Week HighUS$242.73
52 Week LowUS$387.40
Beta1.31
1 Month Change8.10%
3 Month Change11.49%
1 Year Change28.62%
3 Year Change-7.02%
5 Year Change181.06%
Change since IPO5,945.62%

Recent News & Updates

Sep 10

Abiomed: Impella Will Continue To Drive Revenue Growth

Abiomed’s strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company’s Impella range of micro heart pumps will continue to see increasing adoption globally. Long-term investors can buy the company’s shares around the current price to maximize their gain.

Sep 01
Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...

Shareholder Returns

ABMDUS Medical EquipmentUS Market
7D-2.9%-1.0%-0.6%
1Y28.6%34.4%33.7%

Return vs Industry: ABMD underperformed the US Medical Equipment industry which returned 33% over the past year.

Return vs Market: ABMD underperformed the US Market which returned 30.7% over the past year.

Price Volatility

Is ABMD's price volatile compared to industry and market?
ABMD volatility
ABMD Beta1.31
Industry Beta0.87
Market Beta1

Stable Share Price: ABMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: ABMD's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19811,725Mike Minoguehttps://www.abiomed.com

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.

Valuation

Is Abiomed undervalued compared to its fair value and its price relative to the market?

104.38x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABMD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABMD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABMD is poor value based on its PE Ratio (104.4x) compared to the US Medical Equipment industry average (53.7x).

PE vs Market: ABMD is poor value based on its PE Ratio (104.4x) compared to the US market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: ABMD is poor value based on its PEG Ratio (3.4x)


Price to Book Ratio

PB vs Industry: ABMD is overvalued based on its PB Ratio (12.3x) compared to the US Medical Equipment industry average (4.6x).


Future Growth

How is Abiomed forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

31.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABMD's forecast earnings growth (31% per year) is above the savings rate (2%).

Earnings vs Market: ABMD's earnings (31% per year) are forecast to grow faster than the US market (14.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ABMD's revenue (15.4% per year) is forecast to grow faster than the US market (9.5% per year).

High Growth Revenue: ABMD's revenue (15.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ABMD's Return on Equity is forecast to be low in 3 years time (14.4%).


Past Performance

How has Abiomed performed over the past 5 years?

24.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABMD has high quality earnings.

Growing Profit Margin: ABMD's current net profit margins (16.5%) are lower than last year (19.9%).


Past Earnings Growth Analysis

Earnings Trend: ABMD's earnings have grown significantly by 24.4% per year over the past 5 years.

Accelerating Growth: ABMD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ABMD had negative earnings growth (-2.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (31.7%).


Return on Equity

High ROE: ABMD's Return on Equity (11.8%) is considered low.


Financial Health

How is Abiomed's financial position?


Financial Position Analysis

Short Term Liabilities: ABMD's short term assets ($729.9M) exceed its short term liabilities ($113.1M).

Long Term Liabilities: ABMD's short term assets ($729.9M) exceed its long term liabilities ($37.7M).


Debt to Equity History and Analysis

Debt Level: ABMD is debt free.

Reducing Debt: ABMD has no debt compared to 5 years ago when its debt to equity ratio was 0.05%.

Debt Coverage: ABMD has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ABMD has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Abiomed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Mike Minogue (54 yo)

17.42yrs

Tenure

US$14,848,247

Compensation

Mr. Michael R. Minogue, also known as Mike, has been Chief Executive Officer and President of ABIOMED Europe GmbH since April 2004. Mr. Minogue has been Chief Executive Officer, President and Director of A...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD14.85M) is above average for companies of similar size in the US market ($USD11.26M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ABMD's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: ABMD's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Abiomed, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Abiomed, Inc.
  • Ticker: ABMD
  • Exchange: NasdaqGS
  • Founded: 1981
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$16.118b
  • Shares outstanding: 45.38m
  • Website: https://www.abiomed.com

Number of Employees


Location

  • Abiomed, Inc.
  • 22 Cherry Hill Drive
  • Danvers
  • Massachusetts
  • 1923
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 05:01
End of Day Share Price2021/09/15 00:00
Earnings2021/06/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.